Scarica l'app Stockscreener
4.17
11.20%
0.42
Dopo l'orario di chiusura:
4.09
-0.08
-1.92%
Precedente Chiudi:
$3.75
Aprire:
$3.65
Volume 24 ore:
52,617
Relative Volume:
0.08
Capitalizzazione di mercato:
$10.95M
Reddito:
$3.50M
Utile/perdita netta:
$-37.33M
Rapporto P/E:
-4.17
EPS:
-1
Flusso di cassa netto:
$-19.15M
1 W Prestazione:
-6.29%
1M Prestazione:
-42.16%
6M Prestazione:
-76.96%
1 anno Prestazione:
-83.19%
Intervallo 1D:
$3.62
$4.29
Intervallo di 1 settimana:
$3.55
$5.47
Portata 52W:
$3.55
$100.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Nome
Hcw Biologics Inc
Settore
Industria
Telefono
954-842-2024
Indirizzo
2929 N COMMERCE PKWY, MIRAMAR
Confronta HCWB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
4.17 | 10.95M | 3.50M | -37.33M | -19.15M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Hcw Biologics Inc Borsa (HCWB) Ultime notizie
HCW Biologics (NASDAQ:HCWB) Rating Lowered to “Sell” at Wall Street Zen - Defense World
HCW Biologics Sees Strong Investor Interest in June - TipRanks
HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Down 85.9% in May - Defense World
HCW Biologics (NASDAQ:HCWB) Trading Down 7.6% – Here’s What Happened - Defense World
Wall Street Zen Upgrades HCW Biologics (NASDAQ:HCWB) to “Hold” - Defense World
HCW Biologics Meets Nasdaq Listing Requirements in May 2025 - TipRanks
HCW Biologics partners with WY Biotech for immunotherapy By Investing.com - Investing.com South Africa
HCW Biologics Secures Licensing Agreement with WY Biotech - TipRanks
HCW Biologics partners with WY Biotech for immunotherapy - Investing.com Australia
HCW Biologics (HCWB) Secures $7M Upfront License Fee in New Agreement with WY Biotech | HCWB Stock News - GuruFocus
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech - GlobeNewswire
HCW Biologics Engages Armistice in Securities Purchase - TipRanks
HCW Biologics (NASDAQ:HCWB) Price Target Lowered to $35.00 at Maxim Group - Defense World
HCW Biologics (HCWB) Price Target Adjusted by Maxim | HCWB Stock News - GuruFocus
HCWB: Maxim Group Maintains Buy Rating, Lowers Price Target | HC - GuruFocus
HCWB: Maxim Group Maintains Buy Rating, Lowers Price Target | HCWB Stock News - GuruFocus
HCW Biologics Issues Shares Through Warrant Exercise - TipRanks
Insider Buying: Hing Wong Acquires Additional Shares of HCW Biol - GuruFocus
HCW Biologics Enters Securities Purchase Agreement - TipRanks
HCW Biologics (NASDAQ:HCWB) Trading 9.1% Higher – Still a Buy? - Defense World
HCW Biologics Inc Reports Q1 2025 Earnings: Revenue at $5,065, Net Loss Reduced to $2.2 Million - GuruFocus
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - The Manila Times
HCW Biologics Inc. Reports Q1 2025 Financial Results and $5 Million Equity Offering Completion - Nasdaq
HCW Biologics Closes $5 Million Public Offering - TipRanks
HCW Biologics (HCWB) Launches $5M Follow-On Offering - GuruFocus
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - The Manila Times
HCW Biologics Raises Fresh Capital: $5M Follow-On Offering Includes Attractive Warrant Package - Stock Titan
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offer - GuruFocus
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offering | HCWB Stock News - GuruFocus
Three layers of uncertainty - The Globe and Mail
Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales - Benzinga
Trading Halt for HCW Biologics (HCWB) Due to Volatility | HCWB S - GuruFocus
Trading Resumes for HCW Biologics (HCWB) | HCWB Stock News - GuruFocus
HCW Biologics Reports Positive Results For HCW9206 And Opens Commercial Partnership Talks - Nasdaq
HCW Biologics Says Studies Show HCW9206 Fusion Protein Addresses Key Challenges for CAR-T Therapies; Shares Surge - marketscreener.com
HCW Biologics (HCWB) Unveils Innovative Pathway for Enhanced CAR - GuruFocus
HCW Biologics presents novel CAR-T cell enhancer By Investing.com - Investing.com Nigeria
HCW Biologics presents novel CAR-T cell enhancer - Investing.com
HCW Biologics Announces Positive Results of Studies of - GlobeNewswire
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization - TradingView
Friday’s Insider Moves: Top Buys and Sells in US Stocks Revealed By Investing.com - Investing.com South Africa
Friday’s Insider Moves: Top Buys and Sells in US Stocks Revealed - Investing.com
Prediction: Warren Buffett May Be Shifting Out of His Berkshire Hathaway CEO Role, but He's Not Done Investing - The Globe and Mail
Should You Buy Rivian Stock While It Is Still Below $15? - The Globe and Mail
This Well-Known Toy Company Is Set to Be an Outperformer if the Tariff War Continues - The Globe and Mail
Insider Buying: Gary Winer Acquires Shares of HCW Biologics Inc (HCWB) - GuruFocus
Hcw biologics CEO acquires $2.41 million in stock By Investing.com - Investing.com Nigeria
Hcw Biologics Inc Azioni (HCWB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Hcw Biologics Inc Azioni (HCWB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Winer Gary M | Director |
May 16 '25 |
Buy |
7.45 |
1,342 |
9,998 |
4,075 |
| GARRETT SCOTT T | Director |
May 16 '25 |
Buy |
7.45 |
13,423 |
100,001 |
25,505 |
| Winer Gary M | Director |
May 08 '25 |
Buy |
26.00 |
2,308 |
60,008 |
2,733 |
| Wong Hing C | Chief Executive Officer |
May 08 '25 |
Buy |
26.00 |
92,500 |
2,405,000 |
493,857 |
| GARRETT SCOTT T | Director |
May 08 '25 |
Buy |
26.00 |
5,385 |
140,010 |
12,082 |
| Byam Rebecca | Chief Financial Officer |
May 08 '25 |
Buy |
26.00 |
8,462 |
220,012 |
43,010 |
| Flowers Lee | SVP of Business Development |
May 08 '25 |
Buy |
26.00 |
962 |
25,012 |
5,720 |
| Greene Rick S. | Director |
May 08 '25 |
Buy |
26.00 |
962 |
25,012 |
2,066 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):